128 results about "Hepatitis" patented technology

The invention belongs to the technical field of biology, and particularly relates to a mouse hepatitis virus antibody or an antigen binding fragment thereof as well as a preparation method and application thereof. The antibody or the antigen binding fragment thereof can specifically recognize and bind to the mouse hepatitis virus or the NSP3 protein thereof, and has good affinity with the mouse hepatitis virus or the NSP3 protein thereof; the kit can be used for preparing products for diagnosing, preventing and / or treating mouse hepatitis virus infection or diseases caused by the mouse hepatitis virus infection, detecting existence or level of mouse hepatitis virus or NSP3 protein in a sample, screening medicines for preventing and / or treating the mouse hepatitis virus infection or the diseases caused by the mouse hepatitis virus infection, and carrying out basic research and / or vaccine development.

The invention relates to the technical field of hepatitis diagnosis and treatment management, and discloses a block chain-based hepatitis patient full-period management method. The method comprises the following steps: creating a patient identity chain in a block chain network, and storing patient registration data and initial diagnosis information; full-cycle diagnosis and treatment data of a patient are obtained and divided into clinical examination, iconography, medication records and life sign monitoring data. Performing multi-dimensional cleaning on the clinical examination data to generate a standardized data set; inputting the iconography data into a pre-trained hepatitis feature extraction model, and outputting a liver injury feature set; verifying the integrity of the medication record, and generating a non-tampering medication time sequence chain; comparing the life sign monitoring data with preset health reference parameters to generate a sign deviation coefficient set; according to the method, data safety and traceability are guaranteed through the block chain, diagnosis and treatment data quality is improved through multi-dimensional data processing, patient privacy is protected, and reliable support is provided for full-period management of hepatitis patients.

The invention discloses a quantitative index determination method and device based on a hepatitis pathology image, equipment, a medium and a product, and relates to the field of medical pathology image artificial intelligence analysis, and the method comprises the steps: obtaining an image of a liver puncture pathology section; according to the image of the hepatic puncture pathological section, performing feature extraction by using a multi-stage model cascade architecture to obtain a pathological feature result; the multi-stage model cascade architecture comprises an improved VM-UNet segmentation model and a VM classification model based on FEM enhancement, and the VM classification model is connected with the improved VM-UNet segmentation model; the pathological feature result comprises the expansion level of the manifold area, the necrosis type of the manifold area and the inflammatory cell information of the manifold area; and calculating a quantitative index according to the pathological feature result. According to the invention, the accuracy, objectivity, consistency and repeatability of identification can be improved.

The invention provides a polypeptide for activating cellular immunity in chronic hepatitis B and application of the polypeptide, and belongs to the technical field of biological medicine. A polypeptide library is designed and synthesized on the basis of a preS1 structural domain for coding HBV large HBsAg, a full-length core protein Core, a polymerase protein fragment rich in T cell epitopes and an mRNA-PreS1CPX holoantigen sequence (as shown in SEQ ID NO.1) of full-length X protein HBX, and peptide fragments capable of activating T cell immunity are screened by utilizing ELISPOT and flow cytometry. Experimental results show that the polypeptide sequences as shown in SEQ ID NO.2-15 can promote HBV antigen specific immune response by stimulating CD8 + T lymphocytes to secrete IFN-gamma, so that immune activation treatment of hepatitis B is realized.

The present application relates to derivatives of STOPS™ antiviral compounds having enhanced helicity, wherein the compounds are S-antigen transport inhibiting oligonucleotide polymers. This application further relates to processes for making the compounds and methods of using them to treat diseases and conditions. In some embodiments, the diseases and conditions are related to hepatitis B and / or hepatitis D.

The invention provides a nano-phase penthorum chinense pursh extract, which is prepared by the following steps: soaking a penthorum chinense pursh medicinal material, decocting, filtering, collecting filtrate, carrying out layering centrifugation to remove precipitate, dialyzing supernate by adopting a dialysis bag with the molecular weight cutoff of 3.5 kDa, and freeze-drying dialysate to obtain the nano-phase penthorum chinense pursh extract. The invention further provides a preparation method and application of the nanometer phase-state penthorum chinense pursh extract. The invention provides an extraction method capable of accurately separating 50-200nm phase-state active components in a nanometer phase-state penthorum chinense pursh extract traditional Chinese medicine. Organic solvents are prevented from being used, and the safety of extracted products is improved; the purity of the target component is improved; the structural integrity of a natural nanometer phase state is kept; the obtained nanometer phase-state extract has the effects of remarkably improving metabolic dysfunction related steatohepatitis and resisting coagulation, is high in separation efficiency, can be completed in 2-3 days, and can be applied on a large scale; the equipment is simple and low in cost.

The application discloses a tripterine self-assembled nanoparticle microsphere, a preparation method and application thereof, and belongs to the technical field of biological medicines. The tripterine self-assembled nanoparticle microsphere takes tripterine self-assembled nanoparticles as a drug core, is formed by cross-linking of a sodium alginate-pectin composite carrier through calcium ions, can significantly improve drug solubility, realizes stable protection and intestinal targeting rapid release in the gastrointestinal tract, and effectively reduces drug systemic exposure and side effect risks. The preparation process is mild and simple, the obtained preparation has high targeting and safety. Pharmacodynamic results show that the microsphere can obviously improve liver steatosis, inflammation and fibrosis related to metabolic-related fatty liver hepatitis, and has better curative effect than conventional preparations. The application provides a novel oral delivery system for preventing and treating metabolic-related fatty liver hepatitis, and has good industrial and clinical transformation prospects.

The invention discloses a method for predicting the survival state of duck against hepatitis A virus infection. The method comprises the following steps: (1) constructing a PCA (Principal Component Analysis) prediction model by taking the contents of IFN-alpha and IFN-beta of duck blood as variables; (2) measuring the contents of IFN-alpha and IFN-beta in the duck blood to be measured; and (3) substituting the measured contents of IFN-alpha and IFN-beta in the duck blood into the prediction model, and predicting the anti-hepatitis A virus infection survival state of the duck to be detected according to the family background of the individual in combination with the output result of the prediction model. According to the method, ROC curves and corresponding AUC values of different prediction models in the aspect of predicting the survival state are compared, and the result shows that the AUC value of the PCA prediction model is the highest, and the sensitivity and the specificity are most prominent. Based on the prediction model provided by the invention, the Beijing duck individuals or strains with strong disease resistance can be rapidly screened, and the prediction model has an application prospect in duck disease resistance breeding or duck virus hepatitis prevention.

The present invention provides gene therapies for the treatment of Friedreich's ataxia. Specifically, the present invention provides a nucleic acid, cloning vector and transfer vector for the production of an adeno-associated virus (AAV) vector. The nucleic acid comprises (i) a nucleic acid sequence encoding frataxin, (ii) a phospho-glycerate-kinase (PGK) promoter, and (iii) a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). The present invention also provides a pharmaceutical composition which comprises the AAV vector or nucleic acid. Also, the AAV vector, nucleic acid or pharmaceutical composition can be used as a medicament, specifically as a medicament for the treatment of Friedreich's ataxia.

Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents. The pharmaceutical compositions disclosed herein that include AAT RNAi agents, when administered to a human patient in need thereof, treat liver diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, fulminant hepatic failure, and other liver-related diseases.

This invention discloses an anti-hepatitis active composition, its preparation method, and its application. The anti-hepatitis active composition, by mass percentage, comprises 70.3±0.4% cucurbitacin B, 26.1±0.2% isocucurbitacin B, and 3.6±0.3% cucurbitacin E. Using widely available sunflower seed shells as raw material, this invention obtains a high-purity, quality-controllable anti-hepatitis active composition by optimizing the extraction solvent, eluent composition, and chromatographic detection methods, ensuring the uniformity and controllability of TCs quality. Compared with cucurbitacin tablets, the anti-hepatitis active composition of this invention has a higher median lethal dose (LD50) and a NOAEL of 15 mg / kg BW, exhibiting higher safety.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for treating hepatobiliary diseases, the traditional Chinese medicine composition has the effects of soothing liver-gallbladder, clearing away heat and toxic materials, promoting qi circulation, dispersing blood stasis, regulating qi, activating blood, benefiting gallbladder and removing urinary calculus, and is clinically used for treating cholelithiasis, cholecystitis, jaundice, hepatitis and other diseases. The preparation has the advantages of good curative effect, small side effect, low price, convenience in taking and the like, and exerts the unique advantage of the traditional Chinese medicine in treating hepatobiliary diseases.

To provide novel agents for the treatment or prevention of Epstein-Barr virus hepatitis. [Solution] A pharmaceutical composition for the treatment or prevention of Epstein-Barr virus hepatitis in a subject, comprising ibudilast, dipyridamole, or both as active ingredients.

The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,whereinwherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compoundsfor the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).

The application belongs to the technical field of biological detection, and particularly relates to the use of apolipoprotein A-I in the preparation of a diagnostic reagent or system for predicting the risk of severe acute hepatitis E. The application first discloses and verifies the significant correlation between the serum apolipoprotein A-I (apoA-I) level and the adverse clinical outcomes (including severe jaundice, liver failure and death) of patients with acute hepatitis E, and establishes the risk interpretation threshold (0.675 g / L and 0.435 g / L) with clinical practical value. The application can objectively and early identify high-risk patients, and provides a powerful auxiliary tool for clinical stratified management and resource optimization.

The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.

The application provides a liver-protecting medicinal and edible Chinese medicine composition, a medicinal and edible Chinese medicine preparation and a preparation method and application, and specifically belongs to the technical field of medicinal and edible Chinese medicines. The medicinal and edible Chinese medicine composition comprises the following components in parts by weight: Cassia seed 1-3.5 parts, jujube seed 0.5-2.5 parts, Phyllanthus emblica 0.1-1.5 parts and Prunella vulgaris 0.1-1.5 parts. The medicinal and edible Chinese medicine composition has the effects of significantly improving fatty liver and non-alcoholic fatty hepatitis, and can provide a low-cost and non-toxic side-effect strategy for preventing or treating non-alcoholic fatty hepatitis.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies including grade IV glioblastoma with native IDH, grade 3 glioma, embryonal tumour, pituitary tumour, meningioma, haemangiopericytoma, haemangioblastoma, mesothelioma, bile duct adenocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urachal cancer, adenocarcinoma of the bladder and oesophageal cancer, and for the treatment of neuropathic pain caused by diabetic peripheral neuropathy, spinal cord injury, post-herpetic neuralgia, chemotherapeutic agent, antitumour agent, cancer, fibromyalgia or hepatitis. The present invention also relates to the pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-oate.

The present application provides combinations of bulevirtide, or a pharmaceutically acceptable salt thereof, and ribavirin, or a pharmaceutically acceptable salt thereof, useful for treating hepatitis D virus (HDV) infection.

The present invention provides a drug for treating and / or preventing enteritis and / or hepatitis, said drug containing D-amino acid as an active ingredient. In addition, the present invention provides a food composition for suppressing enteritis and / or hepatitis, said composition containing D-amino acid as an active ingredient. In addition, the present invention provides a method for assisting diagnosis of enteritis and / or hepatitis in a subject, said method using the amount of D-amino acid in the intestinal tract as an indicator.

The present application provides combinations of bulevirtide, or a pharmaceutically acceptable salt thereof, and lonafarnib, or a pharmaceutically acceptable salt thereof, useful for treating hepatitis D virus (HDV) infection.

The present application belongs to the field of biomedical detection technology, and particularly relates to a kit for detecting human immunodeficiency virus antibodies and hepatitis E virus antigens in urine based on a latex method, and a test strip for detecting human immunodeficiency virus antibodies and hepatitis E virus antigens in urine based on a latex method. The test strip comprises a base plate, a sample pad, a latex pad, a nitrocellulose membrane and a water absorption pad. The sample pad, the latex pad, the nitrocellulose membrane and the water absorption pad are sequentially and adjacently bonded on the base plate in a chromatographic direction. The nitrocellulose membrane is provided with a quality control line and two detection lines. The quality control line is coated with goat anti-mouse IgG. The two detection lines are respectively coated with streptavidin and HEV monoclonal antibody 2. The latex pad is coated with latex-labeled GP41, GP36, GP120 mixed antigen, GP160 antigen and HEV monoclonal antibody 1. The sample pad is coated with biotin-coupled SPA. The kit disclosed by the present application is convenient to use, simple to operate, and can simultaneously detect HIV antibodies and HEV antigens.

The invention discloses a personalized nursing scheme generation system for hepatitis patients. The personalized nursing scheme generation system comprises a signal acquisition and processing unit, a dynamic decision-making unit and a feedback optimization unit, the signal acquisition and processing unit adopts a flexible wearable hepatic region monitoring patch and a bio-impedance spectroscopy sensor array, acquires data of electrophysiological signals and metabolic characteristics of a patient in real time, and eliminates medical environmental noise from the data; the dynamic decision-making unit is used for cooperatively transmitting data by integrating a fractal antenna array and a medical special LoRaWAN protocol, establishing a three-layer cascade decision-making model, integrating patient medical history, gene detection data and clinical guidelines, and generating a personalized nursing scheme; the feedback optimization unit carries out dynamic optimization processing on the personalized nursing scheme; the multi-modal data of electrophysiological signals, metabolic characteristics, medical history and gene detection are fused to generate a highly personalized nursing scheme, so that patient requirements can be accurately matched, and the accuracy and pertinence of the nursing scheme are improved.

The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.

In one aspect, the disclosure provides a method for identifying whether a subject has or is at increased risk of developing a liver disease (e.g., non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hepatitis, cirrhosis, or cancer), comprising providing a cell-free deoxyribonucleic acid (cfDNA) sample derived from the subject, determining the cfDNA sample or a derivative thereof to determine a methylation pattern or methylation level of a DNA molecule of the cfDNA sample, processing the methylation pattern or methylation level using a trained machine learning (ML) algorithm to generate an output indicative of whether the cfDNA sample is positive for liver disease, and generating, based at least in part on the output, an electronic report indicating that the subject has a liver disease or an increased risk of developing a liver disease.

A system for managing liver disease, the system comprising an electronic medical record system comprising a plurality of patient records. The system comprising a patient management platform configured to access the electronic medical record (EMR) system to retrieve medical records of one or more patients, analyze the medical records to selectively identify data related to a liver condition, interface with one or more data analysis platforms configured to receive and analyze the data related to a liver condition. Based on analysis by the patient management interface and / or the data analysis platforms, a display is generated comprising: specific liver-related patient attributes and conditions, and at least one of: a liver health prognosis or a recommended treatment for addressing the liver condition corresponding to the one or more patients. The liver condition can comprise one or more of: cancer, cirrhosis, liver failure, fatty liver disease, steatosis, ischemia, and / or hepatitis.

At least one pharmaceutical composition for use in a method of prophylaxis or treatment of COVID wherein the at least one pharmaceutical composition comprises donepezil, rivastigmine or galantamine or one of donepezil, rivastigmine or galantamine combined with one of: Artemether and Lumefantrine; Atazanavir Sulfate; Efavirenz; Fosamprenavir Calcium; Saquinavir; Remdesivir (GS-5734); Digoxin; Memantine; Rivastigmine; Galantamine; Valsartan; Teriflunomide and wherein the method of prophylaxis or treatment of COVID or COVID-19 comprises: providing a subject in need of said prophylaxis or treatment; providing the at least one pharmaceutical composition as defined supra; wherein said components are provided together or separately; wherein said components are administered together or separately; and wherein said components are provided in a pharmaceutically acceptable diluent, adjuvant and / or excipient; and administering a pharmaceutically effective amount of said at least one pharmaceutical composition to said subject; and wherein, in the method, said subject is provided prophylaxis or treatment of COVID and COVID relates to a human coronavirus, mouse hepatitis virus (MHV), or recombinant mouse-adapted SARS-CoV (SARS-CoV MAI 5).

The invention discloses application of licoflavone A in resisting viral hepatitis B, and belongs to the technical field of medicine application. The licoflavone A is used for treating viral hepatitis B. The licoflavone A used in the invention shows good safety and tolerance in HepG2.2. 15 and HepG2.A64 cells, can play a role in resisting HBV under the condition of no obvious cytotoxicity, and has significant advantages compared with interferon drugs in the prior art with long treatment course, large side effect and poor tolerance.

The invention discloses a compound enzyme enzymolysis process of a suckling pig liver active peptide as well as a product and application of the suckling pig liver active peptide, and belongs to the technical field of extraction and preparation of functional peptides. The technical problems to be solved are that an adaptive compound enzyme formula is lacked in the existing preparation of the active peptide of the suckling pig liver, the enzymolysis efficiency of a single enzyme or a conventional compound enzyme is low, active peptide components in the suckling pig liver cannot be efficiently released, and the activity is not ideal. In the research and development of bioactive peptides for hepatitis and liver injury, no bioactive peptide from suckling pig liver is efficiently prepared and has a definite liver protection function, and the existing liver protection bioactive peptide has the problems of unstable curative effect and the like. According to the technical scheme, the compound enzyme enzymolysis process is characterized in that compound enzyme is used, and the compound enzyme is composed of neutral protease, papain, trypsin and lipase.

Disclosed herein are nucleic acid compositions and methods of use. The nucleic acid compositions may have a therapeutic nucleic acid sequence operably linked to a nuclear targeting sequence that increases expression of the therapeutic nucleic acid in a cell by at least 1.25 fold; at least 80% sequence identity to SEQ ID NO: 6; or a first regulatory element comprising a promoter sequence operably linked to a hemoglobin subunit gamma intron (hBGi) sequence, and a second regulatory element comprising a woodchuck hepatitis posttranscriptional regulatory element (WPRE) sequence. The nucleic acid compositions with these features may enhance therapeutic nucleic acid transfection and expression. Also disclosed herein are transgenes optimized for gene therapy applications, including novel FVIII transgene sequences, in which the B domain may be non-naturally occurring the A1 and / or A3 domain may include at least one amino acid substitution.